Table 1.
Demographics of subjects at baseline
| Characteristics | CN (n = 52) | sMCI (n = 22) | pMCI (n = 47) | AD (n = 18) |
|---|---|---|---|---|
| Age (years) | 76.2 (5.1) | 76.0 (5.1) | 73.1 (6.6) | 74.3 (7.0) |
| Gender, female (%) | 22 (42.3%) | 7 (31.8%)d | 14 (29.8%)d | 11 (61.1%) |
| Education (years) | 15.7 (3.3) | 16.8 (2.4) | 15.9 (2.7) | 15.2 (2.9) |
| APOE ε4, n (%) | 10 (19.2%)c,d | 7 (31.8%)c,d | 28 (59.6%)a,b | 13 (72.2%)a,b |
| MMSE | 29.3 (1.0)b,c,d | 27.2 (1.4)a,d | 26.6 (1.6)a,d | 24.2 (2.1)a,b,c |
| ADAS-cog | 5.9 (2.8)b,c,d | 9.2 (3.8)a,c,d | 12.5 (4.3)a,b,d | 18.2 (6.1)a,b,c |
| Aβ42 (pg/ml) | 211.4 (56.2)b,c,d | 181.0 (54.7)a,c,d | 147.5 (47.8)a,b | 136.1 (27.3)a,b |
| t-tau (pg/ml) | 72.7 (28.5)c,d | 84.7 (54.0)d | 107.8 (49.3)a,d | 153.2 (78.7)a,b,c |
| t-tau/Aβ42 | 0.399 (0.283)c,d | 0.553 (0.492)c,d | 0.820 (0.501)a,b,d | 1.138 (0.569)a,b,c |
| p-tau (pg/ml) | 24.6 (10.4)c,d | 28.1 (15.7)c,d | 39.5 (16.5)a,b | 45.8 (16.4)a,b |
| p-tau/Aβ42 | 0.135 (0.095)c,d | 0.184 (0.147) c,d | 0.303 (0.162)a,b | 0.350 (0.145)a,b |
| Follow-up (years) | 7.5 (2.6)b,c,d | 4.8 (2.5)a,d | 5.7 (2.6)a,d | 2.6 (0.7)a,b,c |
Values are shown as mean ± standard deviation unless otherwise indicated
p values indicate the values assessed with analyses of variance for each variable except gender and APOE ε4, where a contingency chi-square was performed. Post-hoc analysis provided significant differences between groups: a versus CN; b versus sMCI; c versus pMCI; d versus AD.
Aβ amyloid-β, AD Alzheimer’s disease, ADAS-cog Alzheimer’s Disease Assessment Scale cognitive subscale, APOE apolipoprotein E, CN cognitively normal, MMSE Mini-Mental State Examination, pMCI progressive mild cognitive impairment, p-tau phosphorylated tau, sMCI stable mild cognitive impairment, t-tau total tau